Zevra Therapeutics (ZVRA) is back in focus after reporting better-than-expected Q4 and full-year 2025 earnings, reaching profitability as MIPLYFFA sales, EMA filing plans, and a new GeneDx partnership reshape its rare disease profile.

The stock has pulled back, with a 1-day share price decline of 2.16% to US$10.19. However, recent news around MIPLYFFA, EMA progress, the GeneDx partnership and the new CFO hire comes against a 22.3% 90-day share price return and a 3-year total shareholder return above 100%, suggesting momentum has been building over time.

If Zevra’s rare disease focus has caught your attention, you might also want to see how other specialist biotech names stack up using our 34 healthcare AI stocks as a starting list.

With shares up 22.3% in 90 days and trading at a large discount to the US$22.75 analyst price target, the key question now is whether Zevra still offers upside or if the market is already pricing in future growth.

Most Popular Narrative: 62.1% Undervalued

According to the most followed narrative, Zevra Therapeutics' fair value sits well above the last close of $10.19, putting a spotlight on the gap between price and projected potential.

Zevra Therapeutics is at the most profitable inflection point in biotechnology: the transition from cash-burning R&D to cash-generating commercial sales. With the recent FDA approval of Miplyffa (for Niemann-Pick disease type C), Zevra has secured the first and only approved treatment for this ultra-rare condition. Combined with the sale of its Priority Review Voucher (PRV) for ~$100M non-dilutive cash, the balance sheet is fortified. The market is currently pricing ZVRA as a speculative biotech, failing to account for the high-margin, recurring revenue of a rare disease monopoly.

If you want to see what sits behind that valuation gap, the narrative presents a full revenue ramp, margin profile and profit multiple that together inform its fair value, but keeps one key assumption quietly doing most of the heavy lifting.

Result: Fair Value of $26.89 (UNDERVALUED)

However, this hinges on MIPLYFFA uptake and Azstarys royalties meeting expectations, while any hiccups in late stage trials for KP1077 or Celiprolol could challenge the thesis.

Next Steps

If this mix of optimism and concern feels familiar, it is a good cue to look at the numbers yourself and decide where you stand. You can quickly get context from the balance of 5 key rewards and 1 important warning sign.

Ready to hunt for your next idea?

If Zevra has sharpened your curiosity, do not stop here. The real edge comes from lining up multiple ideas and testing them side by side.

• Target value first and see which names pass the quality bar with our 47 high quality undervalued stocks as a focused shortlist.
• Prioritize resilience by scanning companies that pair financial strength with staying power using the solid balance sheet and fundamentals stocks screener (41 results).
• Boost your income watchlist by reviewing companies in the 15 dividend fortresses that combine yield with staying power in their payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.